Expectations trend
FY2028 · fiscal year ending 2028-09-27 · fmp
Central Garden & Pet Company (CENT)
NASDAQConsumer StaplesPackaged FoodsSnapshot 2026-11-04
$47.94-0.91%
Close 2026-11-05 · 1-day change
NASDAQConsumer StaplesPackaged FoodsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
3.32 → 3.32 EPS · FY ending Sep 27, 2028 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for CENT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain capital expenditures around $50 million annually | Capital spending remains disciplined at about $50 million. | Intact | Capex exceeds $60 million in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 1 supplied quarters. Management reported: “Capital expenditures for fiscal 2026 are projected to be approximately $50 million, focused on maintenance, productivity initiatives, and targeted growth investments across both segments.” “Gross leverage, calculated using the definitions for Indebtedness and EBITDA in Central's credit agreement, ended the third quarter at 2.8x, compared with 2.9x in the prior year and below the target range of 3.0 to 3.5x.” |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-09-27 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 23, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
CENT is a consumer staples company with a growth initiative in European pet supplies, rather than a clear turnaround or speculative growth story. Its long-term thesis is intact, but the signal has shifted from mildly favorable to mixed as valuation fell and earnings quality remains fragile.
CENT is valued cheaply versus peers, and the valuation evidence describes expectations as justified rather than excessively fragile. The expectations gap is negative, so the market setup does not point to unusually high expectations, though the evidence does not specify exactly what future results investors assume.
Near-term fundamentals have been strong, and management raised fiscal 2026 non-GAAP diluted EPS guidance to $2.85 or better. The TRIXIE acquisition is a multi-year growth initiative, but it is expected to close in fiscal 2027 and is not yet reflected in financial results. Earnings quality remains fragile, with a quiet but nonzero miss risk and a history of a deep miss.
A key near-term test is whether CENT can sustain its raised guidance, since reversing course would also hurt management credibility. A weakening jobs trend could add pressure to cyclical businesses, while continued earnings strength and higher guidance from sector peers could support the sector backdrop. Over the multi-year view, the TRIXIE acquisition's execution and contribution are important swing factors.
Over the next 1 to 3 years, CENT’s thesis rests on sustaining recent operating strength and delivering on its European expansion while managing fragile earnings quality. The cheaper-than-peer valuation is a support, but the forward evidence is mixed. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Raise fiscal 2026 non-GAAP diluted EPS to $2.85 or better | They raised EPS guidance to $2.85 for fiscal 2026. | Intact | EPS falls below $2.85 in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 1 supplied quarters. Management reported: “Fiscal 2026 Guidance Reflecting year-to-date results and improved visibility into the balance of the year, Central raises its outlook for fiscal 2026 non-GAAP diluted EPS from $2.70 or better to $2.85 or better, driven by continued margin discipline, ongoing investment in growth initiatives, and portfolio optimization.” “On a non-GAAP basis, operating income totaled $136 million, compared with $139 million, a decrease of only 2%, with operating margin expanding by 90 basis points to 15.4% from 14.5%.” Delivery assessment Nov 3, 2026 |
Improve operating margin to 14.3% or better | A supporting condition in Central Garden & Pet Company's published investment case. The stated target is >=14.3%. | Intact | Operating margin falls below 14.3% | Operating margin: 14.26% FY2026-Q3; GAAP. Published target: >=14.3%. Target period is not explicitly aligned with this observation. Aug 6, 202614.262174 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 1 supplied quarters. Management reported: “Operating income totaled $126 million, compared with $135 million, a decrease of 7%, with operating margin expanding by 20 basis points to 14.3% from 14.1%.” “Gross profit was $317 million, compared with $332 million, a decrease of 5%, with gross margin expanding by 130 basis points to 35.9% from 34.6%.” Delivery assessment Nov 3, 2026 |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$3.32 → $3.32 · observed estimates
$3.19B → $3.19B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-28 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-09-29 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-09-30 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-01 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-02 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-03 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-04 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-05 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-06 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-07 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-08 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-09 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-10 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-11 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-12 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-13 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-14 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-15 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-16 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-17 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-18 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-19 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-20 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-21 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-22 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-23 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-24 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-25 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-26 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-27 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-28 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-29 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-30 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-10-31 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-11-01 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-11-02 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-11-03 | $3.32 | $3,192,922,100 | 1 / 1 |
| 2026-11-04 | $3.32 | $3,192,922,100 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.